Despite toxicity concerns for CD47 targets in 2023, the macrophage therapies space remains determined to drive revolutionary treatments for oncology, autoimmunity, inflammation, neurodegenerative disorders, and beyond. From pioneering the next generation of CAR-M therapies to unveiling novel targets, this field is on a mission to learn from the past and spearhead pipelines into clinical development.

With that, the 6th Macrophage-Directed Therapies Summit will return to Boston this year, uniting 60+ biopharma and academia leaders across R&D, Discovery, Biology, Translational, and Clinical Development fields. As a uniquely positioned platform, this event is perfect for those committed to reigniting excitement in macrophage pipeline advancement.  

This is your chance to gain exclusive insights from industry giants like Verseau Therapeutics, Inceptor Bio, Resolution Therapeutics, and Elpisicence Biopharmaceuticals, as they unravel macrophage biology and accelerate towards proof-of-concept data.